PK of TAF and TDF for PrEP in Pregnant and Postpartum Women
Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This study will establish benchmarks of TFV-DP concentrations as measures of adherence
following daily dosing with Tenofovir Alafenamide (TAF) compared with Tenofovir Disoproxil
Fumarate (TDF) during pregnancy and postpartum. Study Investigators will recruit from an
ongoing observational cohort study in Cape Town, South Africa, PrEP-PP (recruitment ongoing
through July, 2021; NIMH R01MH116771; PI Coates & Myer). Findings form this PK sub-study will
be used to inform future PrEP in pregnancy and postpartum studies and develop benchmarks of
the relative PK between TDF and TAF.
Phase:
Phase 3
Details
Lead Sponsor:
University of California, Los Angeles
Collaborators:
Desmond Tutu HIV Foundation Gilead Sciences University of Cape Town